Bkemv (eculizumab-aeeb)

No dosing information is available for this tab.

No dosing information is available for this tab.

No dosing information is available for this tab.

No formal drug interaction studies have been conducted to date with eculizumab.

There are no contraindication interactions for this drug.

Severe Interaction: Action is required to reduce the risk of severe adverse interaction.

C5 Complement Inhibitors/Crovalimab

SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.

MECHANISM OF ACTION: Crovalimab is a complement C5 inhibitor which binds to epitopes on C5. Other complement C5 inhibitors such as eculizumab and ravulizumab bind to different epitopes on C5. Use of multiple complement inhibitors may lead to formation of drug-target-drug complexes (DTDCs) which may increase the risk of serious type III hypersensitivity reactions.(1)

CLINICAL EFFECTS: Use of multiple complement inhibitors may lead to formation of drug-target-drug complexes (DTDCs) which may increase the risk of serious type III hypersensitivity reactions. Type III hypersensitivity reactions can present as vasculitis, serum sickness, lymphadenopathy with arthralgias, rheumatoid arthritis, or glomerulonephritis.(1)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: The manufacturer of crovalimab states caution is advised when switching patients between other complement C5 inhibitors such as eculizumab or ravulizumab. The formation of drug-target-drug complexes (DTDCs) can occur when switching therapies. DTDCs are expected to be cleared within approximately 8 weeks (with eculizumab) or longer (with ravulizumab). Consider the risks and benefits of the timing of switching therapies with the risk of type III hypersensitivity reactions.(1) Monitor patients closely for signs of type III hypersensitivity reactions.(1) If patients develop a hypersensitivity reaction, for mild or moderate Type III hypersensitivity reactions, administer symptomatic treatment, such as topical corticosteroids, antihistamines, antipyretics, and/or analgesics. For severe reactions, initiate and taper oral or systemic corticosteroids therapy as clinically indicated.(1)

DISCUSSION: Clinical drug interaction studies with crovalimab have not been performed. Use of multiple complement inhibitors may lead to formation of drug-target-drug complexes (DTDCs) which may increase the risk of serious type III hypersensitivity reactions.(1) In clinical trials, type III hypersensitivity reactions were reported in 19% of patients who switched from eculizumab or ravulizumab to crovalimab. Also, type III hypersensitivity reactions were documented in 25% of patients who switched from crovalimab to either eculizumab or ravulizumab.(1)

Igg Antibodies And Derivatives/Efgartigimod-Alfa

SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.

MECHANISM OF ACTION: The neonatal Fc receptor (FcRn) prevents catabolism and mediates recycling of IgG and albumin, which leads to their long persistence in the body.(1,2) Efgartigimod-alfa binds to FcRn and may decrease systemic exposure of other ligands of FcRn, like immunoglobulins and IgG-based antibodies.(3)

CLINICAL EFFECTS: The effectiveness of medicines that bind to FcRn may be decreased.(3)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: The manufacturer of efgartigimod-alfa states that efgartigimod-alfa should not be combined with long-term use of FcRn-binding medications. If the medication is essential for the patient, efgartigimod-alfa should be discontinued.(3)

DISCUSSION: Clinical drug interaction studies with efgartigimod-alfa have not been performed. Efgartigimod-alfa may decrease concentrations of compounds that bind to the human FcRn.(3)

Igg Antibodies And Derivatives/Nipocalimab-Aahu

SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.

MECHANISM OF ACTION: The neonatal Fc receptor (FcRn) prevents catabolism and mediates recycling of IgG and albumin, which leads to their long persistence in the body.(1,2) Nipocalimab-aahu binds to FcRn and may decrease systemic exposure of other ligands of FcRn, like immunoglobulins and IgG-based antibodies.(3)

CLINICAL EFFECTS: The effectiveness of medicines that bind to FcRn may be decreased.(3)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: The manufacturer of nipocalimab-aahu states that nipocalimab-aahu should not be combined with long-term use of FcRn-binding medications. If the medication is essential for the patient, nipocalimab-aahu should be discontinued.(3)

DISCUSSION: Clinical drug interaction studies with nipocalimab-aahu have not been performed. Nipocalimab-aahu may decrease concentrations of compounds that bind to the human FcRn.(3)

Moderate Interaction: Assess the risk to the patient and take action as needed.

Eculizumab/Intravenous Immunoglobulin Therapies

SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.

MECHANISM OF ACTION: Concomitant use of eculizumab products in patients on intravenous immunoglobulin treatment (IVIg) can reduce eculizumab concentrations.(1-2)

CLINICAL EFFECTS: The effectiveness of eculizumab may be decreased.(1-2)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: For patients with generalized myasthenia gravis, the manufacturer of eculizumab states a supplemental dose of eculizumab is required with concomitant use of IVIg treatment. Acute IVIg rescue treatment: No supplemental eculizumab dose needed. IVIg treatment equal to or more frequent than every 4 weeks: -If the most recent eculizumab dose was 900 mg or more, administer a supplemental eculizumab dose of 600 mg at the same scheduled eculizumab dose. -If the most recent eculizumab dose was 600 mg or less, administer a supplemental eculizumab dose of 300 mg at the same scheduled eculizumab dose. IVIg treatment less frequently than every 4 weeks: -If the most recent eculizumab dose was 900 mg or more, administer a supplemental eculizumab dose of 600 mg at the next scheduled eculizumab dose after the last IVIg cycle. -If the most recent eculizumab dose was 600 mg or less, administer a supplemental eculizumab dose of 300 mg at the next scheduled eculizumab dose after the last IVIg cycle.

DISCUSSION: Clinical drug interaction studies with eculizumab have not been performed. IVIg treatment may decrease concentrations of eculizumab.(1)

Igg Antibodies And Derivatives/Rozanolixizumab-Noli

SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.

MECHANISM OF ACTION: The neonatal Fc receptor (FcRn) prevents catabolism and mediates recycling of IgG and albumin, which leads to their long persistence in the body.(1,2) Rozanolixizumab-noli binds to FcRn and may decrease systemic exposure of other ligands of FcRn, like immunoglobulins and IgG-based antibodies.(3)

CLINICAL EFFECTS: The effectiveness of medications that bind to FcRn may be decreased.(3)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: The manufacturer of rozanolixizumab-noli states that concurrent use with medications that bind to the human neonatal Fc receptor (FcRn) should be closely monitored for reduced effectiveness of these medications. If long-term use of such medications is essential for the patient, consider discontinuing rozanolixizumab-noli and use alternative therapies.(3)

DISCUSSION: Clinical drug interaction studies with rozanolixizumab-noli have not been performed. Rozanolixizumab-noli may decrease concentrations of compounds that bind to the human FcRn.(3)

*Patients with unresolved serious Neisseria meningitidis infection.

• Meningococcal meningitis
• Meningococcemia

• Infection

There are no moderate contraindications for this drug.

Adverse effects reported in at least 10% of patients and at a higher incidence than placebo in the PNH clinical studies include headache, nasopharyngitis, back pain, and nausea.

Adverse effects reported in at least 20% of patients (total incidence from 2 studies) in the single-arm prospective aHUS studies include headache, diarrhea, hypertension, upper respiratory infection, abdominal pain, vomiting, nasopharyngitis, anemia, cough, peripheral edema, nausea, urinary tract infections, and pyrexia. h

The most frequently reported adverse effect in at least 10% of patients with generalized myasthenia gravis is musculoskeletal pain.

The most frequently reported adverse effects in at least 10% of patients with NMOSD include upper respiratory infection, nasopharyngitis, diarrhea, back pain, dizziness, influenza, arthralgia, pharyngitis, and contusion.

More Frequent

• Anemia
• Hypertension

Less Frequent

• Aspergillosis
• Cataracts
• Herpes simplex infection
• Hypersensitivity drug reaction
• Hypotension
• Infection
• Leukopenia
• Lymphopenia
• Viral infection

Rare or Very Rare

• Anaphylaxis
• Cardiomyopathy
• Cholestatic hepatitis
• Drug-induced hepatitis
• Goiter
• Gonococcal meningitis
• Hearing loss
• Meningitis
• Meningococcemia
• Septic shock
• Systemic lupus erythematosus
• Thrombocytopenic disorder

More Frequent

• Acute abdominal pain
• Back pain
• Constipation
• Cough
• Diarrhea
• Fatigue
• Fever
• Headache disorder
• Musculoskeletal pain
• Myalgia
• Nausea
• Pharyngitis
• Sinusitis
• Upper respiratory infection
• Urinary tract infection
• Vomiting

Less Frequent

• Alopecia
• Anorexia
• Arthralgia
• Bronchitis
• Bruising
• Cellulitis
• Cystitis
• Dizziness
• Dry skin
• Dysgeusia
• Dyspnea
• General weakness
• Hematoma
• Hordeolum
• Influenza
• Migraine
• Muscle spasm
• Ocular discharge
• Pain
• Pain in oropharynx
• Pruritus of skin
• Rhinitis
• Skin photosensitivity
• Skin rash
• Stomatitis
• Tachycardia
• Vertigo

Rare or Very Rare

• Abdominal distension
• Abnormal hepatic function tests
• Blurred vision
• Conjunctivitis
• Depression
• Dysuria
• Gastroesophageal reflux disease
• Gingival pain
• Nasal congestion
• Palpitations
• Paresthesia
• Peripheral edema

No enhanced messaging available.

Safety and efficacy of eculizumab for the treatment of PNH, myasthenia gravis, or NMOSD have not been established in pediatric patients.

A total of 47 pediatric patients 2 months to 17 years of age were included in the principal efficacy studies of eculizumab for the treatment of aHUS. Safety and efficacy of the drug in these pediatric patients were similar to those in adults.

Pediatric patients receiving eculizumab should receive appropriate vaccinations for the prevention of Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type b (Hib) infections.

Limited data in pregnant women receiving eculizumab have not identified any concerns of adverse developmental outcomes.

There are disease-associated risks to the mother and fetus. Untreated PNH in pregnancy is associated with adverse maternal outcomes (e.g., worsening cytopenias, thrombotic events, infections, bleeding, miscarriages, increased maternal mortality) and adverse fetal outcomes (e.g., fetal death, premature delivery). Similarly, untreated aHUS in pregnancy is associated with adverse maternal outcomes (e.g., preeclampsia, preterm delivery) and adverse fetal/neonatal outcomes (e.g., intrauterine growth restriction, fetal death, low birth weight).

In animal reproduction studies, increased rates of developmental abnormalities and increased rate of dead and moribund offspring were observed.

Detectable levels of eculizumab have not been found in human milk; however, maternal IgG is known to be present in human milk. There is insufficient information to inform the effect of eculizumab on the breast-fed infant. There are no data on the effects of eculizumab on milk production. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for eculizumab and any potential adverse effects on the breast-fed child from the drug or underlying maternal condition.

There is insufficient experience in patients 65 years of age or older to determine whether geriatric patients respond differently than younger patients.